RISK STRATIFICATION WITH PRE-TREATMENT METABOLITE RISK SCORE FOR CARFILZOMIB-RELATED CARDIOTOXICITY IN MULTIPLE MYELOMA PATIENTS.

被引：0
|
作者：
Nguyen, T. [1 ]
Tantawy, M. [1 ]
Zhou, Y. [1 ]
Rubinstein, S. [2 ]
Garrett, T. [1 ]
Baz, R. [3 ]
Fradley, M. [4 ]
Lu, Q. [1 ]
Lenihan, D. [5 ]
Cornell, R. [6 ]
Gong, Y. [1 ]
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Univ N Carolina, Chapel Hill, NC 27515 USA
[3] H Lee Moffitt Canc Ctr Res Inst, Tampa, FL USA
[4] Univ Penn, Philadelphia, PA 19104 USA
[5] Washington Univ, St Louis, MO 63110 USA
[6] Abb Vie, Chicago, IL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PT-014
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [21] MULTIPLE MYELOMA IMMUNOPHENOTYPE RELATED TO CHROMOSOMAL ABERRANCIES USED IN RISK STRATIFICATION
    Radzevicius, Mantas
    Dirse, Vaidas
    Klimiene, Indre
    Matuzeviciene, Reda
    Zvirblis, Tadas
    Kucinskiene, Zita Ausrele
    Peceliunas, Valdas
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 : 145 - 145
  • [22] Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
    Dimopoulos, M. A.
    Sonneveld, P.
    Siegel, D.
    Palumbo, A.
    San-Miguel, J.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2247 - 2256
  • [23] Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma
    Mellgard, George
    Gilligan, Molly
    Cliff, Edward R. Scheffer
    Bhutani, Divaya
    Mohyuddin, Ghulam R.
    Eisenberger, Andrew
    Lentzsch, Suzanne
    Chakraborty, Rajshekhar
    HEMASPHERE, 2024, 8 (03):
  • [24] Risk stratification of patients with newly diagnosed multiple myeloma: Optimizing treatment based on pretreatment characteristics
    Chng, Wee J.
    Fonseca, Rafael
    CLINICAL LYMPHOMA & MYELOMA, 2005, 6 (03): : 200 - 207
  • [25] External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs
    Dima, Danai
    Li, Ang
    Granat, Lauren M.
    Dhillon, Puneet
    Chamseddine, Fatima
    Yalamanchali, Anirudh
    Mirzai, Saeid
    Wei, Wei
    Samaras, Christy J.
    Valent, Jason
    Anwer, Faiz
    Khouri, Jack
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (02) : 280 - 284
  • [26] External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs
    Dima, Danai
    Li, Ang
    Granat, Lauren M.
    Dhillon, Puneet
    Gurnari, Carmelo
    Yalamanchali, Anirudh
    Mirzai, Saeid
    Wei, Wei
    Faiman, Beth M.
    Williams, Louis S.
    Mazzoni, Sandra
    Samaras, Christy J.
    Anwer, Faiz
    Valent, Jason
    Khouri, Jack
    BLOOD, 2022, 140 : 11299 - 11300
  • [27] Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
    Zhao, Fang
    Yang, Bo
    Wang, Juan
    Zhang, Rui
    Liu, Jing
    Yin, Fenglei
    Xu, Weixing
    He, Chunyuan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1525 - 1531
  • [28] Development of a Clinical Risk Stratification for Patients with Newly Diagnosed Multiple Myeloma
    Mao, Xuehan
    Xu, Yan
    Yan, Yuting
    Liu, Jiahui
    Fan, Huishou
    Sui, Weiwei
    Deng, Shuhui
    Li, Zengjun
    Qiu, Lugui
    An, Gang
    BLOOD, 2019, 134
  • [29] Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)
    Mellgard, George
    Gilligan, Molly
    Cliff, Edward R. Scheffer
    Bhutani, Divaya
    Mohyuddin, Ghulam Rehman
    Eisenberger, Andrew
    Lentzsch, Suzanne
    Chakraborty, Rajshekhar
    BLOOD, 2023, 142
  • [30] Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
    Leypoldt, Lisa B.
    Tichy, Diana
    Besemer, Britta
    Haenel, Mathias
    Raab, Marc S.
    Mann, Christoph
    Munder, Markus
    Reinhardt, Hans Christian
    Nogai, Axel
    Goerner, Martin
    Ko, Yon-Dschun
    de Wit, Maike
    Salwender, Hans
    Scheid, Christof
    Graeven, Ullrich
    Peceny, Rudolf
    Staib, Peter
    Dieing, Annette
    Einsele, Hermann
    Jauch, Anna
    Hundemer, Michael
    Zago, Manola
    Pozek, Ema
    Benner, Axel
    Bokemeyer, Carsten
    Goldschmidt, Hartmut
    Weisel, Katja C.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) : 26 - +
12345